Trial Profile
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for hepatitis C after organ transplantation -Pilot Study-
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2018
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 17 May 2018 Status changed from not yet recruiting to completed.
- 18 Feb 2015 New trial record